Scot C. Remick

8.6k total citations · 1 hit paper
156 papers, 6.1k citations indexed

About

Scot C. Remick is a scholar working on Oncology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Scot C. Remick has authored 156 papers receiving a total of 6.1k indexed citations (citations by other indexed papers that have themselves been cited), including 83 papers in Oncology, 38 papers in Molecular Biology and 31 papers in Pathology and Forensic Medicine. Recurrent topics in Scot C. Remick's work include Cancer Treatment and Pharmacology (27 papers), Lymphoma Diagnosis and Treatment (26 papers) and Viral-associated cancers and disorders (26 papers). Scot C. Remick is often cited by papers focused on Cancer Treatment and Pharmacology (27 papers), Lymphoma Diagnosis and Treatment (26 papers) and Viral-associated cancers and disorders (26 papers). Scot C. Remick collaborates with scholars based in United States, Kenya and Uganda. Scot C. Remick's co-authors include Afshin Dowlati, Govardhanan Nagaiah, Nathan Levitan, Alfred A. Rimm, Rebecca J. Beyth, Matthew M. Cooney, John C. Ruckdeschel, Colin Mooney, Pingfu Fu and S. Percy Ivy and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Scot C. Remick

155 papers receiving 5.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Rates of Initial and Recurrent Thromboembolic Disease Among Patients with Malignancy Versus Those without Malignancy: Risk Analysis Using Medicare Claims Data

1999 709 citations Nathan Levitan, Afshin Dowlati et al. profile →

Peers

Countries citing papers authored by Scot C. Remick

Since Specialization

Citations

This map shows the geographic impact of Scot C. Remick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scot C. Remick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scot C. Remick more than expected).

Fields of papers citing papers by Scot C. Remick

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scot C. Remick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scot C. Remick. The network helps show where Scot C. Remick may publish in the future.

Co-authorship network of co-authors of Scot C. Remick

This figure shows the co-authorship network connecting the top 25 collaborators of Scot C. Remick. A scholar is included among the top collaborators of Scot C. Remick based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scot C. Remick. Scot C. Remick is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Comparative risk of obesity-related cancer with glucagon-like protein-1 receptor agonists vs. bariatric surgery in patients with BMI ≥ 35. 2024 ·Journal of Clinical Oncology ·Cindy Lin, Benjamin P. Liu, (unknown), Jiasheng Wang, Xiaonan Han, Scot C. Remick, William Ka Fai Tse, (unknown)	3
2	Targeting the secreted RGDKGE collagen fragment reduces PD‑L1 by a proteasome‑dependent mechanism and inhibits tumor growth 2023 ·Oncology Reports ·(unknown), Xianghua Han, Christine W. Lary, Pradeep Sathyanarayana, Scot C. Remick, Marc S. Ernstoff, Meenhard Herlyn, Peter C. Brooks	1
3	Disability-Adjusted Life-Years Due to Stroke in Kenya 2019 ·Neuroepidemiology ·Lydia Kaduka, Erastus Muniu, Jane Mbui, (unknown), (unknown), Judith Kwasa, (unknown), (unknown), Anne Korir, Scot C. Remick	5
4	Sorafenib and thyroid cancer 2014 ·Expert Review of Endocrinology & Metabolism ·(unknown), (unknown), (unknown), (unknown), Manish Monga, Scot C. Remick	33
5	Randomized Safety and Efficacy Study of Fosbretabulin with Paclitaxel/Carboplatin Against Anaplastic Thyroid Carcinoma 2013 ·Thyroid ·Julie Ann Sosa, Rossella Elisei, Barbara Jarząb, Jai Balkissoon, (unknown), Chandrasekhar Bal, Shanthi Marur, Ann W. Gramza, R. Ben Yosef, Barbara J. Gitlitz, Bryan R. Haugen, Frank G. Ondrey, Charles Lu, (unknown), Fadlo R. Khuri, Lisa Licitra, Scot C. Remick	116
6	EGFR inhibition in non-small cell lung cancer: current evidence and future directions 2013 ·Biomarker Research ·Alexander Chi, Scot C. Remick, William Tse	28
7	Phase I trial of pomalidomide given for patients with advanced solid tumors 2012 ·Cancer Chemotherapy and Pharmacology ·Matthew M. Cooney, Charles Nock, Joseph A. Bokar, Smitha Krishnamurthi, Joseph Gibbons, (unknown), (unknown), Scot C. Remick, Robert Dreicer, Afshin Dowlati	7
8	Anaplastic Thyroid Cancer: A Review of Epidemiology, Pathogenesis, and Treatment 2011 ·Journal of Oncology ·Govardhanan Nagaiah, Akm Hossain, Colin Mooney, James Parmentier, Scot C. Remick	223
9	Higher infused CD34+ cell dose and overall survival in patients undergoing in vivo T-cell depleted, but not t-cell repleted, allogeneic peripheral blood hematopoietic cell transplantation 2011 ·Hematology/Oncology and Stem Cell Therapy ·Abraham S. Kanate, Michael Craig, Aaron Cumpston, Ayman Saad, Gerry Hobbs, (unknown), (unknown), Katherine E. Watkins, (unknown), Laura F. Gibson, Jame Abraham, Scot C. Remick, Mehdi Hamadani	4
10	Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan‐based reduced toxicity conditioning 2011 ·Hematological Oncology ·Mehdi Hamadani, Michael Craig, Gary Phillips, Jame Abraham, William Tse, Aaron Cumpston, Laura F. Gibson, Scot C. Remick, (unknown), (unknown), Patrick Elder, Craig C. Hofmeister, Sam Penza, Yvonne A. Efebera, Leslie A. Andritsos, Ramiro Garzon, Don M. Benson, William Blum, Steven M. Devine	11
11	Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study 2011 ·Cancer Chemotherapy and Pharmacology ·(unknown), Scot C. Remick, Chris H. Takimoto, Ramesh K. Ramanathan, Angela M. Davies, Merrill J. Egorin, Anne Hamilton, Patricia LoRusso, Stephen Shibata, Heinz Josef Lenz, James W. Mier, John Sarantopoulos, Sridhar Mani, James R. Wright, S. Percy Ivy, Rachel Neuwirth, Lisa Von Moltke, Karthik Venkatakrishnan, Daniel Mulkerin	35
12	Factors Influencing Adherence to Mammography Screening Guidelines in Appalachian Women Participating in a Mobile Mammography Program 2011 ·Journal of Community Health ·Ami Vyas, Suresh Madhavan, (unknown), (unknown), (unknown), (unknown), Kimberly M. Kelly, Linda Vona‐Davis, Scot C. Remick	36
13	Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors 2010 ·JNCI Journal of the National Cancer Institute ·Michael L. Maitland, George L. Bakris, Henry R. Black, Helen X. Chen, Jean‐Bernard Durand, W.J. Elliott, S. Percy Ivy, Carl V. Leier, JoAnn Lindenfeld, Glenn Liu, Scot C. Remick, Richard M. Steingart, W.H. Wilson Tang	300
14	A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment 2009 ·Cancer Chemotherapy and Pharmacology ·Christopher J. Sweeney, Chris H. Takimoto, Leslie Wood, J. Porter, William Tracewell, Mona Darwish, Denise D’Andrea, Scot C. Remick	23
15	A phase I study of rebeccamycin analog in combination with oxaliplatin in patients with refractory solid tumors 2009 ·Investigational New Drugs ·Charles Nock, Joanna M. Brell, Joseph A. Bokar, Matthew M. Cooney, Brenda Cooper, Joseph Gibbons, Smitha Krishnamurthi, Sudhir Manda, P. Savvides, Scot C. Remick, Percy Ivy, Afshin Dowlati	17
16	Phase II study of bryostatin 1 and vincristine for aggressive non‐Hodgkin lymphoma relapsing after an autologous stem cell transplant 2009 ·American Journal of Hematology ·Paul M. Barr, Hillard M. Lazarus, Brenda Cooper, Mark Schluchter, Ashok Panneerselvam, James W. Jacobberger, Jack W. Hsu, Nalini Janakiraman, (unknown), Afshin Dowlati, Scot C. Remick	54
17	Confirmation of Gene Expression–Based Prediction of Survival in Non–Small Cell Lung Cancer 2008 ·Clinical Cancer Research ·Nancy Lan Guo, Ying-Wooi Wan, Kürşad Tosun, Hong Lin, (unknown), Daniel C. Flynn, Scot C. Remick, Val Vallyathan, Afshin Dowlati, Xianglin Shi, Vincent Castranova, David G. Beer, Yong Qian	81
18	A phase I pharmacokinetic and pharmacodynamic study of SU5416 and Adriamycin in inflammatory breast cancer 2001 ·Breast Cancer Research and Treatment ·Beth Overmoyer, Kelly M. Robertson, (unknown), (unknown), Jesse M. Lewin, John A. Jesberger, Nicholas P. Ziats, Kou‐Yi Tserng, Charles L. Hoppel, Paul Hartman, Jay Wasman, Fadi W. Abdul‐Karim, (unknown), Brian Cooper, Carol A. Connell, James M. Pluda, Keith R. McCrae, Scot C. Remick	13
19	Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancer 2001 ·Cancer Chemotherapy and Pharmacology ·Afshin Dowlati, Nathan Levitan, Nahida H. Gordon, Charles L. Hoppel, (unknown), Scot C. Remick, Stephen T. Ingalls, S J Berger, Nathan A. Berger	20
20	Human herpesvirus-8–associated disseminated angiosarcoma in an HIV-seronegative woman: report of a case and limited case-control virologic study in vascular tumors 2000 ·The American Journal of Medicine ·Scot C. Remick, Madhumita Patnaik, Navid Ziran, (unknown), Jennifer Dong, Afshin Dowlati, Yao Yao, Fadi W. Abdul‐Karim, Chou‐Zen Giam	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact